Next Article in Journal
Cholesterol and Oxidative Stress in U.S. Pregnant Women Exposed to Lead
Previous Article in Journal
Chromosomal Microarray Analysis versus Karyotyping in Fetuses with Increased Nuchal Translucency
Open AccessReview

Dually Efficacious Medicine Against Fibrosis and Cancer

Research Institute of Biological Medicine, Yiling Pharmaceutical, Beijing 102600, China
Med. Sci. 2019, 7(3), 41; https://doi.org/10.3390/medsci7030041
Received: 16 December 2018 / Revised: 18 February 2019 / Accepted: 25 February 2019 / Published: 4 March 2019
(This article belongs to the Section Cancer and Cancer-Related Research)
Although there is a contemporary consensus of managing a severe disease with multi-targeted approach-based therapeutic combinations, it should not be ignored that certain patho-biological pathways are shared by distinct medical conditions and can be exploited to develop an exceptional type of medication conferring a dual efficacy. This article thus presents a spectrum of emerging molecular targets that substantially contribute to the pathogenesis of both fibrotic and neoplastic disorders, including kinase activities, cytokine cascades, and protein dynamics among others. Moreover, recently approved therapeutic agents in this regard have been sorted out to corroborate the drug’s ability upon targeting each one of these molecular pathways to treat fibrosis and cancer simultaneously. It not only streamlines an overlapping mechanistic profile in the pathogenesis across these two medical conditions, but also inspires clinicians and pharmaceutical innovation to tackle concomitant diseases, such as fibrosis and cancer, with an optimally efficacious medication. View Full-Text
Keywords: dual efficacy; fibrosis; cancer dual efficacy; fibrosis; cancer
MDPI and ACS Style

Chen, D. Dually Efficacious Medicine Against Fibrosis and Cancer. Med. Sci. 2019, 7, 41.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop